Y-mAbs Announces Data to be Presented at 2021 ASCO Annual Meeting
NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer is pleased to announce the acceptance of two poster presentations for DANYELZA and an oral presentation for omburtamab at the American Society of Clinical Oncology (“ASCO”) Virtual Annual Meeting, taking place virtually from June 4, 2021 to June 8, 2021. The presentations were submitted by Dr. Brian Kushner, Memorial Sloan Kettering Cancer Center (“MSK”), Dr. Jaume Mora, M.D., Ph.D., SJD Barcelona Children's Hospital and Dr. Mark Souweidane, MSK and Weill Cornell Medicine:
Researchers at MSK developed DANYELZA and omburtamab, which are exclusively licensed by MSK to Y-mAbs. As a result of this licensing arrangement, MSK has institutional financial interests in the products.
“Y-mAbs®” and “DANYELZA®” are registered trademarks of Y-mAbs Therapeutics, Inc.